medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2022, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2022; 69 (2)

Utility of nuclear cells to hematoprogenitors collection in autologous transplantation of autoimmune diseases

Alvarado-Navarro DM, Chávez-Estrada YO, Moncada-Saucedo NK, Hernández-Navarro AK, Ake-Uc MB, Gómez-De LA, Salazar-Riojas R

Language: Spanish
References: 9
Page: 61-64
PDF size: 191.33 Kb.


ABSTRACT

Introduction: the CD34+ is useful for predict the optimal time to start hematopoietic progenitor cell (HPC) apheresis; however, it is a limited resource, and may not be available. In contrast, the quantification of total nucleated cells (CNT), is accessible and can guide the clinical practice of apheresis. Objective: to evaluate the usefulness of CNT to predict the optimal time to start apheresis of HPC in autologous transplants with autoimmune diseases. Material and methods: data from 256 patients with autoimmune disease with auto transplantation were included, and data were evaluated by recording CD34+ and CNT results before apheresis. The utility of CNT to predict the optimal time to start apheresis and obtain a CD34+ harvest > 2 × 106/kg was evaluated. Results: before apheresis, the median CNT was 1.4 k/µL; and CD34+ 59.5/µL. The ROC analysis of CNT before apheresis with CD34+ > 2 × 106/kg was 0.75 (CI 95% 0.67-0.84, p < 0.001), with a cut off 0.95 k/µL of CNT. Conclusions: the optimal time to predict to start HPC apheresis and harvest > 2 × 106/kg, in patients with autoimmune disease, is when obtaining > 0.95 k/µL.


REFERENCES

  1. Alexander T, Greco R, Snowden JA. Hematopoietic stem cell transplantation for autoimmune disease. Annu Rev Med. 2021; 72: 215-228.

  2. Balassa K, Danby R, Rocha V. Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med (Lond). 2019; 80 (1): 33-39.

  3. Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci. 2017; 56 (2): 190-198.

  4. Remberger M, Torlén J, Ringdén O, Engstrom M, Watz E, Uhlin M et al. Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21 (5): 889-893.

  5. Pura Krishnamurthy K, Sarathy V, Jayappa SB, Badarkhe GV, Kumar Ks R, Thianeshwaran S et al. Study of peripheral mononuclear cells and CD34 levels as a predictive marker for initiating apheresis in autologous stem cell transplant. Int J Hematol Oncol Stem Cell Res. 2021; 15 (3): 170-177.

  6. Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña AA, Olivares-Gazca JC, Priesca-Marín JM, Ruiz-Delgado GJ et al. The 1,000th transplant for multiple sclerosis and other autoimmune disorders at the HSCT-México program: a myriad of experiences and knowledge. Front Neurol. 2021; 12: 647425.

  7. Gutensohn K, Magens MM, Kuehnl P, Zeller W. Increasing the economic efficacy of peripheral blood progenitor cell collections by monitoring peripheral blood CD34+ concentrations. Transfusion. 2010; 50 (3): 656-662.

  8. Fontao-Wendel R, Lazar A, Melges S, Altobeli C, Wendel S. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother. 1999; 8 (3): 255-262.

  9. Yang SM, Chen H, Chen YH, Zhu HH, Zhao T, Liu KY. Dynamics of monocyte count: a good predictor for timing of peripheral blood stem cell collection. J Clin Apher. 2012; 27 (4): 193-199.




2020     |     www.medigraphic.com